IP Library Granted Patent US 10,040,842
Granted Patent B2
US 10,040,842 · App. 14/921,589 · Granted Aug 7, 2018

Fibronectin type III domain based scaffold compositions, methods and uses

Inventors: Steven Jacobs (North Wales, PA); Karyn O'Neil (Media, PA)
Assignee: Janssen Biotech, Inc.
C07K14/78C40B40/08C40B50/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,040,842
App. No.
14/921,589
Granted
Aug 7, 2018
Kind
B2
Abstract

A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.

Claims (15)

1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a protein scaffold comprising the amino acid sequence of SEQ ID NO:16.

2. An isolated nucleic acid vector comprising the isolated nucleic acid molecule of claim 1 .

3. A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid molecule of claim 1 .

4. The host cell of claim 3 , wherein said host cell is at least one selected from E. coli BL21Star(DE3), other E. coli cell, yeast, COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

5. The isolated nucleic acid molecule of claim 1 , comprising the nucleotide sequence set forth in SEQ ID NO:17.

6. An isolated nucleic acid vector comprising the isolated nucleic acid molecule of claim 5 .

7. A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid molecule of claim 5 .

8. The host cell of claim 7 , wherein said host cell is at least one selected from E. coli BL21Star(DE3), other E. coli cell, yeast, COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

9. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a protein scaffold based on a fibronectin type III (FN3) domain comprising:

a backbone portion having an amino acid sequence identical to SEQ ID NO:16 at residues 1-21, 29-74, and 82-89;

a B:C loop portion between residues 21 and 29 of SEQ ID NO:16 having at least 75% identity to residues 22-28 of the amino acid sequence of SEQ ID NO:16; and

an F:G loop portion between residues 74 and 82 of SEQ ID NO:16 having at least 75% identity to residues 75-81 of the amino acid sequence of SEQ ID NO:16.

10. An isolated nucleic acid vector comprising the isolated nucleic acid molecule of claim 9 .

11. A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid molecule of claim 9 .

12. The host cell of claim 11 , wherein said host cell is at least one selected from E. coli BL21Star(DE3), other E. coli cell, yeast, COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2019
From: JACOBS, STEVEN; O'NEIL, KARYN
To: CENTOCOR ORTHO BIOTECH INC.
Reel/Frame 049735/0195 →
CHANGE OF NAME Recorded Jul 12, 2019
From: CENTOCOR ORTHO BIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 049745/0469 →
Continuity (3)
Division 13595484 · Aug 27, 2012
Division 12606382 · Oct 27, 2009
Related Publication 20160039909A1 · Feb 11, 2016